Physician profile
Tulia Gonzalez
NPI 1629319975
$1,924.74
in general payments reported to CMS, 2019-2025
35 companies · $32.24 in 2025
The $32.24 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $893 · 2022: $621 · 2023: $337 · 2024: $40.79 · 2025: $32.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $384.89 | 2021-2023 | Opdivo, Opdualag |
| Celgene Corporation | $260.88 | 2021-2023 | Reblozyl, Pomalyst |
| Beigene USA, INC. | $102.24 | 2021-2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $98.19 | 2022-2025 | |
| Gilead Sciences, INC. | $85.42 | 2021-2023 | Trodelvy |
| Genzyme Corporation | $77.56 | 2021-2023 | |
| Seagen INC. | $73.34 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $71.66 | 2021-2023 | Imbruvica |
| Amgen INC. | $71.11 | 2021-2022 | |
| Abbvie INC. | $70.63 | 2021-2024 | |
| Janssen Biotech, INC. | $68.72 | 2021-2022 | |
| Astellas Pharma US INC | $62.84 | 2021 | |
| Foundation Medicine, INC. | $44.51 | 2022-2023 | |
| Lilly USA, LLC | $42.48 | 2021 | |
| Eisai INC. | $31.06 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.44 | 2021-2022 | |
| Tersera Therapeutics LLC | $25.47 | 2022 | |
| Myovant Sciences INC. | $24.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $24.76 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.48 | 2021 | |
| Deciphera Pharmaceuticals INC. | $22.21 | 2021 | |
| Pfizer INC. | $21.93 | 2023 | |
| Adc Therapeutics America, INC. | $19.84 | 2022 | |
| Incyte Corporation | $19.30 | 2022 | |
| Servier Pharmaceuticals LLC | $19.22 | 2021 | |
| Mirati Therapeutics, INC. | $18.18 | 2023 | Krazati |
| Blueprint Medicines Corporation | $18.00 | 2022 | |
| Tg Therapeutics, INC. | $17.78 | 2022 | |
| Glaxosmithkline, LLC. | $16.64 | 2021 | |
| Epizyme, INC. | $15.49 | 2022 | |
| Taiho Oncology, INC. | $13.64 | 2022 | |
| Dendreon Pharmaceuticals LLC | $13.47 | 2021 | |
| Dova Pharmaceuticals | $12.71 | 2021 | |
| Myriad Genetic Laboratories, INC. | $12.25 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tulia Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.